News Sentiment

IMNM sentiment intelligence

Immunome Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 23.35 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-1.1% over one week, +27.0% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data

Market Reaction

Balanced read

69/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -1.1% Price digesting
Trend fit Trend inactive 27.0% over four weeks
Fair value 65.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 9
MT Newswires 6
simplywall.st 5
Moomoo 3
Investing.com 3
Investing.com Nigeria 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 9
Analyst action 7
Guidance 1
Regulatory and legal 1
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Simply Wall Street Direct company coverage

Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data

Immunome (IMNM) shares dropped 8.2% despite the FDA accepting its New Drug Application (NDA) for varegacestat, a gamma secretase inhibitor for desmoid tumors, with a PDUFA target date of April 28, 2027. The acceptance is based on strong Phase 3 data showing significant improvemen

Tone
Neutral 50/100
Event
Analyst action
Published
16 Jul 2026 23:10
Source
Simply Wall Street
Moomoo Direct company coverage

Truist Financial Maintains Immunome(IMNM.US) With Buy Rating

Truist Financial has reiterated its Buy rating on Immunome (IMNM.US). This suggests a continued positive outlook from the firm regarding the company's stock performance.

Tone
Positive 76/100
Event
Guidance
Published
10 Jul 2026 17:09
Source
Moomoo
Sahm Direct company coverage

Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors

Immunome (IMNM) shares rose 11.7% after the FDA accepted its New Drug Application (NDA) for varegacestat, a treatment for desmoid tumors. The NDA, with a PDUFA target action date of April 28, 2027, is based on Phase 3 data showing an 84% reduction in risk of progression or death.

Tone
Positive 72/100
Event
Analyst action
Published
10 Jul 2026 15:40
Source
Sahm
Market source Direct company coverage

Immunome Stock Up 32% in a Month: Here's What You Should Know

Immunome (IMNM) shares have risen 32% in the last month, driven by investor confidence in its lead asset, varegacestat, and broader clinical progress. The FDA has accepted Immunome's new drug application for varegacestat for desmoid tumors, with a decision expected by April 28, 2

Tone
Positive 72/100
Event
Market update
Published
10 Jul 2026 15:40
Source
Market source
Investing.com Direct company coverage

Immunome CBO Horn Kinney sells $27,300 in stock

Immunome Inc.'s Chief Business Officer, Horn Kinney, sold 1,092 shares of common stock for $27,300 after exercising employee stock options. This sale followed a 172% return on the stock over the past year, though InvestingPro analyses suggest the stock is overvalued. Kinney now h

Tone
Positive 64/100
Event
Market update
Published
10 Jul 2026 05:40
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Immunome Inc For: 9 July By Investing.com

This article from Investing.com announces the filing of a Form 4 for Immunome Inc. on July 9. The main content is a brief statement, with the majority of the page consisting of navigation, market data, and related news headlines. The article itself is very minimalist, providing l

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 02:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Immunome Inc. (IMNM) CBO exercises options and sells 1,092 shares

Immunome Inc.'s Chief Business Officer, Horn Kinney, exercised employee stock options to acquire 1,092 shares at $12.92 per share and subsequently sold all 1,092 shares at $25.00 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on Ma

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:39
Source
Stock Titan
Investing.com Nigeria Direct company coverage

H.C. Wainwright reiterates Immunome stock rating on FDA filing By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $40.00 price target for Immunome Inc. (NASDAQ:IMNM) following the FDA’s acceptance of its new drug application for varegacestat. The company's stock has seen a significant 170% gain over the past year, with ongoing positive analys

Tone
Positive 90/100
Event
Analyst action
Published
09 Jul 2026 12:10
Source
Investing.com Nigeria
Benzinga Direct company coverage

Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review

Immunome (NASDAQ: IMNM) announced that the FDA has accepted its New Drug Application (NDA) for varegacestat, an oral gamma secretase inhibitor, for treating desmoid tumors. The FDA has set a target action date of April 28, 2027. Clinical data from the Phase 3 RINGSIDE trial showe

Tone
Positive 94/100
Event
Analyst action
Published
08 Jul 2026 17:40
Source
Benzinga
Oncodaily Direct company coverage

FDA Accepts Immunome's NDA for Varegacestat in Desmoid Tumors, Setting Up an April 2027 Decision

The FDA has accepted Immunome's New Drug Application (NDA) for varegacestat, an investigational oral gamma secretase inhibitor, for adult patients with desmoid tumors, setting an April 28, 2027, PDUFA action date. This decision is based on strong results from the Phase 3 RINGSIDE

Tone
Positive 71/100
Event
Regulatory and legal
Published
08 Jul 2026 17:40
Source
Oncodaily
Moomoo Direct company coverage

LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40

LifeSci Capital has reiterated its Buy rating for Immunome (IMNM.US) and maintained a target price of $40. This indicates continued confidence in the company's prospects from the analyst firm. Investors will likely watch Immunome's performance in light of this maintained positive

Tone
Positive 72/100
Event
Analyst action
Published
08 Jul 2026 17:10
Source
Moomoo
Caledonian Record Direct company coverage

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome, Inc. announced that the U.S. FDA has accepted its New Drug Application (NDA) for varegacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 20

Tone
Positive 70/100
Event
Analyst action
Published
08 Jul 2026 17:10
Source
Caledonian Record
Seeking Alpha Direct company coverage

Immunome granted FDA review for tumor candidate (IMNM:NASDAQ)

Immunome Inc. (IMNM) announced that the U.S. FDA has accepted its marketing application for varegacestat, a drug developed to treat desmoid tumors. This marks a significant step for the company's lead asset. The application is targeted specifically at adult patients suffering fro

Tone
Positive 91/100
Event
Market update
Published
08 Jul 2026 13:39
Source
Seeking Alpha
grafa.com Direct company coverage

Immunome secures FDA review for cancer drug varegacestat

Immunome's oral tumor treatment, varegacestat, has been accepted for New Drug Application review by the FDA after showing an 84% reduction in the risk of disease progression or death in Phase 3 trials. The FDA has set a Prescription Drug User Fee Act target action date of April 2

Tone
Positive 73/100
Event
Analyst action
Published
08 Jul 2026 11:55
Source
grafa.com
Stock Traders Daily Direct company coverage

Price-Driven Insight from (IMNM) for Rule-Based Strategy

This article provides a price-driven analysis of Immunome Inc. (NASDAQ: IMNM) for rule-based trading strategies, highlighting strong sentiment across all horizons and significant risk-reward opportunities. It details specific trading strategies for different risk profiles, includ

Tone
Positive 71/100
Event
Market update
Published
08 Jul 2026 04:52
Source
Stock Traders Daily
Business Wire Direct company coverage

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. announced that its Compensation Committee granted inducement awards consisting of non-statutory stock options to 17 new employees. These options cover an aggregate of 344,000 shares of common stock, with an exercise price of $21.49, vesting over four years accordin

Tone
Positive 64/100
Event
Market update
Published
08 Jul 2026 04:40
Source
Business Wire
Stock Titan Direct company coverage

Immunome (IMNM) CMO exercises 55K options and sells 55K shares under 10b5-1 plan

Immunome Inc.'s Chief Medical Officer, Robert Lechleider, exercised 55,000 employee stock options at $8.73 per share on July 2, 2026. On the same day, he sold 55,000 common shares in open-market transactions, averaging prices between $21.95 and $23.44 per share, as part of a pre-

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 04:11
Source
Stock Titan
Investing.com Direct company coverage

Immunome CMO Robert Lechleider sells $1.24m in company stock

Immunome Inc.'s Chief Medical Officer, Robert Lechleider, sold 55,000 shares of company stock for $1,244,330, following the exercise of employee stock options. The transactions were conducted under a Rule 10b5-1 trading plan, and analysts largely maintain bullish price targets fo

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 04:11
Source
Investing.com
BioSpace Direct company coverage

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 7, 2026

Immunome, Inc. announced inducement grants of non-statutory stock options for 344,000 shares to seventeen new employees. These awards, approved by the Compensation Committee on July 1, 2026, fall under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. The op

Tone
Positive 58/100
Event
Market update
Published
08 Jul 2026 03:36
Source
BioSpace
Investing.com Direct company coverage

Immunome director Isaac Barchas sells $2.4m in shares, price $24.11-$24.20

Immunome Inc. Director Isaac Barchas sold 100,000 shares of common stock for approximately $2.4 million across two transactions on July 6 and July 7, 2026, with prices ranging from $24.11 to $24.20 per share. These sales were executed via a Rule 10b5-1 trading plan after the stoc

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 00:11
Source
Investing.com
Stock Titan Direct company coverage

Entity tied to Immunome (IMNM) director sells 100K shares

An entity associated with Immunome (IMNM) director Isaac Barchas, AMBHMC II LLC, sold 100,000 shares of the company's common stock on July 6 and 7, 2026. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted average prices of approximately $24.11

Tone
Negative 19/100
Event
Market update
Published
08 Jul 2026 00:11
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Immunome Inc For: 7 July By Investing.com

Investing.com reports on a Form 4 filing for Immunome Inc. on July 7th, 2026. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of company stock. The article itself simply states the filing event without providing additional detail

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 22:11
Source
Investing.com Canada